GC Cell and Bifarma Partner for Cell Therapy Advancements

GC Cell, a prominent cell and gene therapy company, has recently joined forces with Bifarma, a key player in stem cell therapy in Indonesia. This strategic partnership aims to bring cutting-edge cell therapies, such as 'Immuncell-LC' for liver cancer, to the Indonesian market. The collaboration also includes technology transfer and joint efforts in developing NK cell therapy pipelines.

GC Cell's latest Blueprint 2.0 strategy is centered around global expansion, with a specific focus on entering the Asia-Pacific region. Indonesia's increasing population and advancements in healthcare make it a promising market for cell therapies. By leveraging Bifarma's expertise and the infrastructure of Kalbe Group, GC Cell is gearing up to introduce Immuncell-LC in Indonesia.

James Park, the CEO of GC Cell, emphasized the partnership's potential to establish a strong presence in the anti-cancer cell therapy sector. Dr. Sandy Qlintang, the President Director of PT Bifarma Adiluhung, expressed excitement about the collaboration, underlining their dedication to delivering advanced and safe cell therapies.

GC Cell offers a wide range of bio healthcare solutions, while Bifarma's Regenic division stands as Indonesia's leading provider of cell-based therapies. Kalbe Farma Tbk, the parent company of Bifarma, is a major pharmaceutical player in Southeast Asia with diverse product portfolios and digital service ecosystems.

The partnership between GC Cell and Bifarma marks a significant advancement in the global healthcare landscape, aiming to improve patient care and foster innovation in cell therapy.